Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AngioDynamics (ANGO) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AngioDynamics is one of 996 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AngioDynamics is currently sporting a Zacks Rank of #1 (Strong Buy).Over the past 90 days, the Zacks Consensus Estimate for ANGO's full-year earnings has moved 22.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.Based on the most recent data, ANGO has returned 9.2% so far this year. Meanwhile, the Medical sector has returned an average of -5.6% on a year-to-date basis. This means that AngioDynamics is outperforming the sector as a whole this year.Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 18.8%.The consensus estimate for Chugai Pharmaceutical Co., Ltd. Unsponsored ADR's current year EPS has increased 18.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).To break things down more, AngioDynamics belongs to the Medical - Instruments industry, a group that includes 85 individual companies and currently sits at #90 in the Zacks Industry Rank. On average, stocks in this group have lost 8.9% this year, meaning that ANGO is performing better in terms of year-to-date returns.In contrast, Chugai Pharmaceutical Co., Ltd. Unsponsored ADR falls under the Medical - Drugs industry. Currently, this industry has 161 stocks and is ranked #69. Since the beginning of the year, the industry has moved +0.2%.Investors interested in the Medical sector may want to keep a close eye on AngioDynamics and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR as they attempt to continue their solid performance.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks